Relevant bibliographies by topics / Pharmaceutical industry – Italy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Reports

Academic literature on the topic 'Pharmaceutical industry – Italy'

Author: Grafiati
Published: 10 March 2023
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical industry – Italy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical industry – Italy"

1

Ciliberti, Stefano, Laura Carraresi, and Stefanie Bröring. "Drivers of innovation in Italy: food versus pharmaceutical industry." British Food Journal 118, no. 6 (June 6, 2016): 1292–316. http://dx.doi.org/10.1108/bfj-10-2015-0405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Airaghi, R., S. Berlingozzi, S. Cannata, G. Dal Negro, E. Melloni, and F. Motta. "Routine laboratory analysis for preclinical research in the pharmaceutical industry in Italy: An overview." Comparative Haematology International 4, no. 3 (September 1994): 136–42. http://dx.doi.org/10.1007/bf00798353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patarnello, Francesca, Emiliano Briante, and Federico Villa. "Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness." Global & Regional Health Technology Assessment 9 (October 5, 2022): 117–22. http://dx.doi.org/10.33393/grhta.2022.2440.

Full text
Abstract:
Pharmaceutical industry investments in Italy must be supported with a reform process that promotes simplifications to generate an attractive ecosystem that can enhance innovation. Key actions include facilitating the start-up of clinical trials, promoting public-private partnerships to support technology transfer, integrating data infrastructures to overcome the logic of silos, expanding programs for prevention and early identification of diseases, simultaneous reimbursement for therapy and diagnostic testing, and launching a structural program for early access to therapies. The total contribution of the sector in the last 10 years to the Italian economy was € 315 bn. Looking at employment (67 thousand people employed in the sector in 2020), it is possible to estimate about 280 thousand jobs activated in Italy just in 2020. An Altems study quantified a leverage effect of 2.77 in terms of benefits to the Italian NHS from direct investment in clinical research, which means that for every € 1 invested by companies in clinical trials, € 1.77 of additional savings were generated for the NHS. Applying the multiplier on R&D investments of the entire pharmaceutical sector in 2020 (€ 1.6 bn), we could estimate approximately € 4.4 bn in benefits for the NHS. In addition to these benefits there are the noneconomic benefits of clinical research, including early access for patients to innovative therapies, resulting in improved clinical outcomes and quality of life for patients and caregivers in general.
APA, Harvard, Vancouver, ISO, and other styles
4

Jurkowski, Joseph Henry, and Dion D. Daly. "MINTS The Next Economic Frontier for Investment – A Financial Analysis of the Pharmaceutical Industry." International Journal for Innovation Education and Research 4, no. 8 (August 31, 2016): 132–45. http://dx.doi.org/10.31686/ijier.vol4.iss8.581.

Full text
Abstract:
We have heard a great deal recently of the BRIC countries (Brazil, Russia, India, China), and the PIGS (Portugal, Italy, Greece, Spain) but now the focus seems to be on the MINT countries, (Malaysia, Indonesia, Nigeria, and Turkey) as the leading emerging economies in the world. Rising labor and other costs now have companies looking for new opportunities in rapid growth markets. But not without specific risks that companies must be willing to take. Corruption, rampant communicable disease, drug abuse and criminal activity, religious issues and disagreements are a few of the challenges companies must face in the new frontier. This paper will attempt to look at four pharmaceutical companies in each of the MINT countries to determine their potential profitability as an investment opportunity. This industry is especially unique since these countries have a growing population which will increase the labor force and also create a need for pharmaceutical products. Each of these countries is located in an advantageous geographical location which will provide an advantage in growing their economies. Mexico is next to the U.S. and the rest of Latin America. Indonesia is located in the heart of Southeast Asia with strong ties to China. Turkey has positioned itself to have both Eastern and Western influences. Nigeria is in a prime spot as it ls located in the prime economic powerhouse of a continent, Africa. If they get their acts together, solve their problems of corruption, energy, and infrastructure, these four countries could potentially overtake China as a leading economy of the world.
APA, Harvard, Vancouver, ISO, and other styles
5

Guseo, Renato, Alessandra Dalla Valle, Claudia Furlan, Mariangela Guidolin, and Cinzia Mortarino. "Pre-launch forecasting of a pharmaceutical drug." International Journal of Pharmaceutical and Healthcare Marketing 11, no. 4 (November 6, 2017): 412–38. http://dx.doi.org/10.1108/ijphm-07-2016-0036.

Full text
Abstract:
Purpose The emergence of a pharmaceutical drug as a late entrant in a homogeneous category is a relevant issue for strategy implementation in the pharmaceutical industry. This paper aims to suggest a methodology for making pre-launch forecasts with a complete lack of information for a late entrant. Design/methodology/approach The diffusion process of the emerging entrant is estimated using the diffusion dynamics of pre-existing drugs, after an appropriate assessment of the drug’s entrance point. The authors’ methodology is applied to study the late introduction of a pharmaceutical drug in Italy within the category of ranitidine. Historical data of seven already active drugs in the category are used to assess and estimate ex ante the dynamics of a late entrant (Ulkobrin). Findings The results of applying the procedure to the ranitidine market reveal a high degree of accuracy between the ex post observed values of the late entrant and its ex ante mean predicted trajectory. Moreover, the assessed launch date corresponds to the actual date. Research limitations/implications The category has to be homogeneous to ensure a high degree of similarity among the existing drugs and the late entrant. For this reason, radical innovations cannot be forecast with this methodology. Originality/value The proposed approach contributes to the still challenging research field of pre-launch forecasting by estimating the dynamic features of a homogeneous category and exploiting them for forecasting purposes.
APA, Harvard, Vancouver, ISO, and other styles
6

Negro, Carmine, Alessio Aprile, Andrea Luvisi, Luigi De Bellis, and Antonio Miceli. "Antioxidant Activity and Polyphenols Characterization of Four Monovarietal Grape Pomaces from Salento (Apulia, Italy)." Antioxidants 10, no. 9 (September 1, 2021): 1406. http://dx.doi.org/10.3390/antiox10091406.

Full text
Abstract:
The wine industry annually produces millions of tons of by-products rich in polyphenolic compounds that can be reused as secondary raw material in the food, cosmetic and pharmaceutical industries. The purpose of this work was to describe the presence of nutraceutical compounds and to evaluate the antioxidant activity of pomaces from three Apulian (South Italy, Italy) grape varieties (Negroamaro, Malvasia di Lecce and Primitivo) and to compare them with one of the most cultivated wines in Europe (Cabernet Sauvignon). The main classes of polyphenolic substances were characterized via high performance liquid chromatography/diode array detector/mass spectrometer time of flight (HPLC/DAD/TOF) and the antioxidant activity was evaluated with three different methods. The four investigated grape marcs have shown different polyphenols and antioxidant activities. Primitivo marc showed the higher antioxidant activity due to the excellent level of polyphenols, followed by the Negroamaro cultivar. In addition, marcs from traditional Apulian vines showed higher antioxidant activities than Cabernet Sauvignon because of an elevated level of active polyphenolic substances such as catechin, epicatechin, quercetin and its derivatives.
APA, Harvard, Vancouver, ISO, and other styles
7

Cornago, Dante, and Livio Garattini. "Il mercato dei dispositivi per stomia in cinque paesi europei: lezioni per l’Italia." Farmeconomia. Health economics and therapeutic pathways 2, no. 2 (June 15, 2001): 115–23. http://dx.doi.org/10.7175/fe.v2i2.724.

Full text
Abstract:
Aim of the present study is to analyze the international market of the ostomy devices in Italy, France, Germany, U.K. and Denmark. The ostomy systems are technologically mature devices, and the more interesting market developments are about innovative modality of distribution and patients technical support, like home distribution. For every country it has been applied a common pattern, based on four aspect of the ostomy devices market: 1. the legislative aspect; 2. the prescription procedure; 3. the different models of distribution; 4. the competitive systems of pharmaceutical industry. All the data in this study has been galthered through relevant literature and interviews with the area operators. The ostomy devices are repayable against medical prescription in all the studied countries; significant legislative differences are registered in the repayment prices determination. For all the studied countries, in the decisional process related to the choice of one or another device, the essential role is played by the ostomy hospital nurse, that advises the patient immediately after the surgery. Finally, the more significant examples to innovate purchase and distribution process of ostomy devices in Italy comes from Denmark and U.K., where the home distribution is already available and it is working.
APA, Harvard, Vancouver, ISO, and other styles
8

Lazorenko, Valeriia, Liudmyla Saher, and Adam Jasnikowski. "Web management as a marketing management determinant: case for pharmaceutical enterprises." Health Economics and Management Review 2, no. 2 (2021): 105–14. http://dx.doi.org/10.21272/hem.2021.2-10.

Full text
Abstract:
Nowadays, the online business is fast-growing since it is convenient, more profitable, and less energy-consuming. The changing consumers’ needs force companies and organizations to adjust and modernize their marketing strategies. The authors emphasized that Internet advertising channels would overcome the traditional ones. Therefore, it is relevant to consider the latest trends in e-commerce to provide effective advertising campaigns. This study aims to conduct the competitive analysis of Ukrainian veterinary enterprises’ websites as one of the key marketing management determinants. The study object are the most prominent Ukrainian veterinary enterprises. The methodological basis for this paper includes trend, bibliometric, and comparative content analysis. The trend analysis results showed a constant interest in web management worldwide. In turn, there are significant fluctuations over the previous five years in Ukraine. The findings indicated that search requests for «pharmaceutics» worldwide are gradually increasing, while there is not enough statistic data in Ukraine. The bibliometric analysis for Scopus publications addressed the marketing management in the pharmaceutical were visualized by 4 clusters. The first cluster covers marketing, management, and risk issues; the second – pharmaceutical industry, the third – economy; and the fourth – quality control. The findings showed that veterinary medicine was mostly associated with drug efficacy, management, investment, management, risk, organization and management, patents, and quality control. This issue has been most actively studied by scientists from the United States, Britain, Germany, India, and Italy. This study provided the comparative analysis of veterinary enterprises web sites based on the main indicators as follows: usability, site structure, site indexation, number of external pages, overall traffic, behavioral factors (bounce rate, pages per visit, time on site), traffic sources (direct, referrals, SEO, SMM, e-mail, and display advertising), and adaptability to the mobile versions. The obtained results showed that all Ukrainian biological vaccines manufacturers for animals were represented on the Internet. In turn, as of September 2020, Biotestlab most effectively used the Internet to promote products. In second place is the Sumy Biological Factory, and then – Kherson Biological Factory.
APA, Harvard, Vancouver, ISO, and other styles
9

Eandi, Mario, and Carlo Della Pepa. "I farmaci “generici” in Italia: opportunità di ricerca e sviluppo di prodotti di qualità a prezzi competitivi." Farmeconomia. Health economics and therapeutic pathways 4, no. 2 (June 15, 2003): 65–76. http://dx.doi.org/10.7175/fe.v4i2.770.

Full text
Abstract:
Every drug whose copyright coverage has expired can be manufactured by a pharmaceutical company other than the one that developed it, giving rise to the market of the so-called generic drugs. It can be distinguished among two types of generic drugs: branded and unbranded, according to the choice of the manufacturer to assign it a fantasy name or to sell it with the name of the active principle, followed by the company’s name. In order to be accepted for marketing, every new drug has to pass the registration procedures of the Italian Ministry of Health, which are simplified for generics, as it’s sufficient to demonstrate the bioequivalence, considered a reliable proxy of therapeutic equivalence, of the new drug with the standard formulations it copies. The bioequivalence of two drugs depends on various parameters, related to the quality of the raw materials employed and the industrial processes they go through. There are several ways of assessing the equivalence between pharmaceutical products, and it is important the registration studies are conducted following strict rules, in order to guarantee the quality of generics, fundamental for achieving the trust of health operators and patients. The reason to be of generic drugs is essentially economic, as they bare no therapeutic innovation, and their introduction is mainly aimed to contain drug expenditures and to facilitate a competitive market, but to do so, they need to be widely accepted by the medical community and the population. In Italy, the market of generic drugs is very young and relatively underdeveloped if compared to what is observed in other industrialized countries such as the USA, Germany or UK, but it has a good expansion potential, as it also represents a chance for quality enhancement for the Italian pharmaceutical industry.
APA, Harvard, Vancouver, ISO, and other styles
10

Mohammad, Al Sayasneh, O. A. Ruban, I. V. Kovalevska, and O. M. Ievtushenko. "Аnalysis of the market of medicinal products for the conservative treatment of hemorrhoids in order to determine the marketing opportunities for a domestic manufacturer." Social Pharmacy in Health Care 8, no. 4 (December 19, 2022): 46–58. http://dx.doi.org/10.24959/sphhcj.22.274.

Full text
Abstract:
The spread of diseases of the rectum, namely hemorrhoids, leads to the deterioration of the physical and psychological health of the working-age population, increases the budget costs of the healthcare system, insurance companies, and the population’s own funds. In this regard, the development of new complex medicinal products is always relevant for domestic pharmacy. Aim. To form a modern idea of the market structure and trends in the consumption of drugs for the conservative treatment of hemorrhoids, determine the possible potential for domestic developers and manufacturers. Materials and methods. The research was conducted using the structural analysis logical and graphic methods, methods of marketing analysis. Results. It was found that recently the market of antihemoroidal agents for topical application and capillary-stabilizing agents developed quite vigorously – the market growth rates in the period of 2020-2021 were from 15 to 23 % in physical units and from 28 to 40 % in monetary units. However, according to the structure of the producing countries, the market remains import-dependent. Drugs from France, Switzerland, Bulgaria, Germany, Spain, Slovenia, Italy, and the United States are available on the market. The leaders of sales are products manufactured by Servier (France), Innotek International (France), and Teva (Israel). The leaders in the supply of domestic drugs of this group are Borshchagovsky Chemical Pharmaceutical Plant, JSC “Galichpharm”, Kyiv Vitamin Plant, PJSC “Darnitsa” Pharmaceutical company”, PJSC “Monpharm”. The most popular dosage forms are tablets, capsules, gels, ointments, suppositories. Conclusions. Based on the changes identified, certain proposals have been developed for the domestic pharmaceutical industry – the market has a relatively small range of domestic complex medicines combining components of chemical and natural origin, including the plant raw material. The market has a positive development trend; therefore, further search for an effective complex drug is expedient.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical industry – Italy"

1

HERRMANN, Andrea. "Alternative pathways to competitiveness within developed capitalism : a comparative study of the pharmaceutical sector in Germany, Italy and the UK." Doctoral thesis, 2006. http://hdl.handle.net/1814/6578.

Full text
Abstract:
Examining board: Prof. Colin Crouch (University of Warwick), Supervisor ; Prof. David Soskice (Wissenschaftszentrum Berlin; London School of Economics) ; Prof. Rikard Stankiewicz (European University Institute, Florence) ; Prof. Wolfgang Streeck (Max-Planck-Institut für Gesellschaftsforschung, Köln), external co-supervisor
Defence date: 20 November 2006
The present research project questions the central argument of the literature on competitiveness: that firms in the same economy specialise in the same competitive strategy (Heckscher 1919; Ohlin 1933; Sinn 2005; Lundvall 1992; Nelson 1993; Porter 1990; Hall and Soskice 2001). Given that national institutions provide one set of input factors, as required for one specific competitive strategy, this body of literature expects firms to exploit such institutional advantages by pursuing the institutionally favoured strategy. Contrary to these expectations, my analysis of the pharmaceutical sector shows that firms in Germany, Italy and the UK pursue (1) a radical-innovation-, (2) a high-quality-, and (3) a low-cost- strategy to the same extent. Aiming at understanding how firms can pursue different strategies within the same institutional environment, my research project explores the link between (national) institutions, input factors and competitive strategies. In so doing, I first test whether the competitiveness literature rightly suggests that each competitive strategy requires a specific set of input factors. Finding this hypothesis to hold true, I then analyse how firms secure required factors in diverse institutional environments. Exploring different institutional pathways to firm competitiveness, I show that the competitiveness literature falls short in its overly narrow focus on national institutions: The literature simply ignores the fact that firms secure input factors not only through national institutions, but also through 'improvisation* on a contractual basis, and through *importation ' by drawing on international institutions. This finding has two implications. Firstly, given the variety of institutions on which firm competitiveness is based, national institutions do not assume their shape with the aim of supporting one specific production regime. Hence, I retain a historical account more useful to explain institutional development than the functionalist explanations proposed in the competitiveness literature. Secondly, the inventiveness of entrepreneurs in securing required input factors indicates that they are Schumpeterian innovators rather than institutionally constrained actors. Accordingly, a Schumpeterian perception of entrepreneurs is more instructive for understanding how firms gain international competitiveness than the approach of the competitiveness literature, which perceives entrepreneurs as mere institution-takers. These insights lead me to conclude that the increasing internationalisation of economic affairs entails divergence in the shape of institutions, and convergence in entrepreneurial practices.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical industry – Italy"

1

One political economy, one competitive strategy?: Comparing pharmaceutical firms in Germany, Italy, and the UK. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

EPHMRA/ESOMAR Seminar on 1993 and Beyond (1991 Milan, Italy). EPHMRA/ESOMAR Seminar on 1993 and Beyond: A pivotal period for pharmaceutical marketing research? : Milan, Italy, 6th-8th March 1991. Amsterdam, The Netherlands: ESOMAR, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Montanaro, Silvestro. Mister & Lady Poggiolini. Napoli: T. Pironti, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Herrmann, Andrea M. One Political Economy, One Competitive Strategy?: Comparing Pharmaceutical Firms in Germany, Italy, and the UK. Oxford University Press, Incorporated, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

EPHMRA/ESOMAR Seminar on 1993 and Beyond: A pivotal period for pharmaceutical marketing research? : Milan, Italy, 6th-8th March 1991. Esomar, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Skredderberget, Asle. The Oslo conspiracy: A thriller. 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical industry – Italy"

1

Atella, Vincenzo, Jay Bhattacharya, and Lorenzo Carbonari. Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy. Cambridge, MA: National Bureau of Economic Research, December 2008. http://dx.doi.org/10.3386/w14567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical industry – Italy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography